# Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

> **NCT00741273** · PHASE1 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 16 (actual)

## Conditions studied

- Impaired Liver Function

## Interventions

- **DRUG:** Proellex

## Key facts

- **NCT ID:** NCT00741273
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-05
- **Final completion:** 2009-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741273, "Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00741273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*